Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
May 22, 2026
Deere & Company (DE) Beats Q2 Estimates and Holds Full-Year Guidance

Deere & Company (DE) Beats Q2 Estimates and Holds Full-Year Guidance

Key Takeaways

  • Deere & Company reported net income of $1.773 billion, or $6.55 per share, for the second quarter ended May 3, 2026, beating consensus estimates of $5.70 per share.
  • Worldwide net sales and revenues rose 5% year-over-year to $13.369 billion, with equipment operations net sales up 5% to $11.778 billion.
  • Net income for the first half of fiscal 2026 totaled $2.429 billion, or $8.97 per share, compared with $2.673 billion, or $9.82 per share, in the prior-year period.
  • The company maintained its full-year fiscal 2026 net income guidance of $4.5 billion to $5.0 billion.
  • Strong performance in Small Ag & Turf and Construction & Forestry segments helped offset softness in large agricultural equipment.
  • Management highlighted portfolio diversification, dealer network strength, and ongoing investments in innovation as key supports for long-term growth.

Placing the Results in Context

Deere & Company operates on a fiscal year ending in late October, with quarters aligned to agricultural and construction cycles rather than calendar quarters. The second quarter fiscal 2026 results, covering the period ended May 3, 2026, arrive amid ongoing pressure in global agricultural markets from lower farm incomes and commodity price volatility. I find it useful to monitor these reports closely for signals on equipment demand, margin trends, and management’s ability to navigate cyclical downturns through diversification into construction, turf, and precision technology. Strong execution here can influence sentiment toward the broader industrials sector and DE’s ability to sustain market share gains.

Breaking Down the Reported Numbers

Deere & Company delivered second quarter fiscal 2026 net income of $1.773 billion ($6.55 per diluted share), compared with $1.804 billion ($6.64 per share) in the year-ago quarter. Worldwide net sales and revenues increased 5% to $13.369 billion. Equipment operations net sales rose 5% to $11.778 billion. For the first six months, net income reached $2.429 billion ($8.97 per share). The company beat consensus EPS expectations of $5.70 by a wide margin. Management maintained full-year fiscal 2026 net income guidance in the $4.5 billion to $5.0 billion range, citing resilience from a diversified portfolio despite challenges in large agricultural equipment. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

How the Market Viewed the Update

Shares of DE typically experience heightened volatility around earnings releases as investors digest demand signals from key segments. The second quarter fiscal 2026 beat on earnings and maintained guidance provided a positive surprise relative to concerns over agricultural softness. Market participants focused on the strength in construction and small agriculture businesses, which helped offset larger equipment weakness and reinforced confidence in the company’s diversified model. Sentiment heading into the report reflected cautious optimism tied to infrastructure spending and dealer inventory management.

What I’m Watching Going Forward

Deere & Company’s maintained full-year guidance underscores management’s view that diversification across segments and geographies provides a buffer against agricultural market cycles. Investors will watch for updates on large agricultural equipment order books and retail sales trends, which remain sensitive to farm income, commodity prices, and biofuel demand.

Continued strength in construction equipment, supported by infrastructure spending and rental fleet replacement, represents a key growth area. Small Ag & Turf performance will also merit attention as turf markets recover and livestock sectors show healthy cash flows.

Management emphasized ongoing investments in new products, precision technology, and the dealer network as drivers of long-term value. Cost discipline, supply chain stability, and any updates on tariff or trade policy impacts could influence margins in coming quarters. The company’s ability to expand market share while navigating industry headwinds will remain central to performance through the rest of fiscal 2026.

Refining My Research Process with Tickeron Tools

In my own workflow, I frequently turn to Tickeron’s AI Screener to help filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. AI Screener

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: DE

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


DE sees MACD Histogram just turned negative

DE saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 25, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 44 instances where the indicator turned negative. In 29 of the 44 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 66%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for DE moved out of overbought territory on September 24, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 19 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 58%.

The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DE as a result. In 49 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 58%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.

DE broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 43 of 64 cases where DE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.

Following a +3.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where DE advanced for three days, in 199 of 332 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.

The Aroon Indicator entered an Uptrend today. In 124 of 210 cases where DE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 59%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 15 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. DE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 49 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: DE's P/B Ratio (6.645) is slightly higher than the industry average of (2.582). P/E Ratio (38.332) is within average values for comparable stocks, (34.809). Projected Growth (PEG Ratio) (1.600) is also within normal values, averaging (1.745). Dividend Yield (0.009) settles around the average of (0.009) among similar stocks. DE's P/S Ratio (3.868) is very high in comparison to the industry average of (1.128).

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

Notable companies

The most notable companies in this group are Caterpillar (NYSE:CAT), Deere & Company (NYSE:DE).

Industry description

The industry designs and builds agricultural, construction and other large commercial and transportation equipment. Tractors, planters and harvesters, as well as rock-crushing, railroad, demolition and other construction implements are produced by this industry. Rapid urbanization and industrialization has been bolstering the expansion of the construction sector in the past few decades, thereby boosting demand for heavy equipment businesses. Caterpillar Inc., Deere & Company and Cummins Inc (Ex. Cummins Engine Inc) are some prominent companies in this industry.

Market Cap

The average market capitalization across the Trucks/Construction/Farm Machinery Industry is 26.26B. The market cap for tickers in the group ranges from 2.64K to 376.91B. CAT holds the highest valuation in this group at 376.91B. The lowest valued company is ZEVY at 2.64K.

High and low price notable news

The average weekly price growth across all stocks in the Trucks/Construction/Farm Machinery Industry was 2%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was 4%. XOS experienced the highest price growth at 27%, while HCAI experienced the biggest fall at -13%.

Volume

The average weekly volume growth across all stocks in the Trucks/Construction/Farm Machinery Industry was -5%. For the same stocks of the Industry, the average monthly volume growth was -39% and the average quarterly volume growth was -36%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 49
Price Growth Rating: 57
SMR Rating: 78
Profit Risk Rating: 80
Seasonality Score: 32 (-100 ... +100)
View a ticker or compare two or three
DE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of agricultural, industrial, commercial and consumer equipment

Industry TrucksConstructionFarmMachinery

Industry
Trucks Or Construction Or Farm Machinery
Address
One John Deere Place
Phone
+1 309 765-8000
Employees
73100
Web
https://www.deere.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.